ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,177.58
0.44%
Dow Jones
38,778.10
0.49%
Gold vs US Dollar
2,315.57
-0.21%
Brent Oil
83.535
-0.44%
Bitcoin
65,749.96
-1.11%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Moleculin Biotech Inc (MBRX)

  7. Moleculin Biotech Inc (MBRX) News

Moleculin Biotech (MBRX)

Moleculin Biotech Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MBRX
DateTimeSourceHeadlineSymbolCompany
14/06/202413:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
14/06/202413:00PR Newswire (US)Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical TrialNASDAQ:MBRXMoleculin Biotech Inc
12/06/202414:00PR Newswire (US)Moleculin to Present at the Virtual Investor Pitch ConferenceNASDAQ:MBRXMoleculin Biotech Inc
07/06/202422:05Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:MBRXMoleculin Biotech Inc
05/06/202413:55PR Newswire (US)Moleculin to Participate in the Virtual Investor Lunch Break SeriesNASDAQ:MBRXMoleculin Biotech Inc
16/05/202413:32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
16/05/202413:32PR Newswire (US)Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid CongressNASDAQ:MBRXMoleculin Biotech Inc
15/05/202413:38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
15/05/202413:38PR Newswire (US)Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)NASDAQ:MBRXMoleculin Biotech Inc
14/05/202421:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
13/05/202415:53Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:MBRXMoleculin Biotech Inc
13/05/202412:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
13/05/202412:30PR Newswire (US)Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:MBRXMoleculin Biotech Inc
10/05/202421:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MBRXMoleculin Biotech Inc
09/05/202413:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
09/05/202413:30PR Newswire (US)Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for AnnamycinNASDAQ:MBRXMoleculin Biotech Inc
08/05/202413:45PR Newswire (US)Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and WebcastNASDAQ:MBRXMoleculin Biotech Inc
08/05/202413:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
07/05/202421:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
07/05/202413:55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
07/05/202413:55PR Newswire (US)Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject DataNASDAQ:MBRXMoleculin Biotech Inc
02/05/202414:00PR Newswire (US)Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024NASDAQ:MBRXMoleculin Biotech Inc
01/05/202413:50PR Newswire (US)Moleculin Announces Formation of Scientific Advisory Board to Support Development of AnnamycinNASDAQ:MBRXMoleculin Biotech Inc
18/04/202413:30PR Newswire (US)European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)NASDAQ:MBRXMoleculin Biotech Inc
10/04/202413:30PR Newswire (US)Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic PropertiesNASDAQ:MBRXMoleculin Biotech Inc
28/03/202414:45PR Newswire (US)Moleculin to Present at the MedInvest Biotech & Pharma Investor ConferenceNASDAQ:MBRXMoleculin Biotech Inc
27/03/202413:25PR Newswire (US)Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin OpportunityNASDAQ:MBRXMoleculin Biotech Inc
27/03/202413:05PR Newswire (US)Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AMLNASDAQ:MBRXMoleculin Biotech Inc
25/03/202411:30PR Newswire (US)Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML TrialNASDAQ:MBRXMoleculin Biotech Inc
22/03/202420:05PR Newswire (US)Moleculin Reports Full Year 2023 Financial ResultsNASDAQ:MBRXMoleculin Biotech Inc
 Showing the most relevant articles for your search:NASDAQ:MBRX

Your Recent History

LSE
SCE
Surface Transforms
LSE
QBT
Quantum Blockchain Techn...
LSE
BIRD
Blackbird
LSE
GKP
Gulf Keystone Petroleum
LSE
TERN
Tern
LSE
OXB
Oxford Biomedica
LSE
AAZ
Anglo Asian Mining
LSE
CPX
Cap-xx
LSE
CHLL
Chill Brands
LSE
HE1
Helium One Global
LSE
AFC
Afc Energy
LSE
VAST
Vast Resources
LSE
SBTX
Skinbiotherapeutics
LSE
POS
Plexus
LSE
EEE
Empire Metals
LSE
I3E
I3 Energy
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved